The National AIDS Treatment Advocacy Project - NATAP - provides the latest in HIV and AIDS drug research and treatment information as well as comprehensive reports and developments from the Fifth Retroviruses and Opportunistic Infections conference, as well as from the ICAR, ICAAC, IDSA, European and International HIV and AIDS conferences, and from other sources.

POST VANCOUVER TREATMENT REPORTS

• Nevirapine Interaction Data with Indinavir (11/26/96)

• Consensus Statement on 1592 Expanded Access and Accelerated Approval (11/24/96)

• Delavirdine FDA Hearing (11/24/96)

• Merck Announces Extension of Temporary Tracking Distribution System (modified 11/11/96)

• Preliminary results of ongoing delavirdine-protease inhibitor interaction studies ---exact text of description from Pharmacia & Upjohn (10/6/96)

• Agouron Announces Expanded Access Program (9/17/96)

• Nevirapine Update (9/17/96)

• Nelfinavir Pediatrics Study (9/17/96)

• Delavirdine Interaction Studies -- Caution! (9/17/96)

• Nelfinavir: Preliminary Efficacy & Safety Data Update (9/3/96)

• Perspectives on Viral Load (HIV RNA) and When to Initiate Therapy (8/26/96)

• PMPA Update (8/14/96)

• Nelfinavir Resistance Profile (8/15/96)

• 1592U89: An update of preliminary safety & antiviral data (8/9/96)

• Newly Infected Subjects: Triple Therapy with AZT/3TC and Ritonavir (modified 11/16/96)

• Combination Use of Ritonavir and Saquinavir in HIV-Infected Patients (8/5/96) -Preliminary Safety and Activity Data

• Stavudine (d4T) and Didanosine (ddI) Combination Therapy in HIV-Infected Subjects (8/5/96) Antiviral Effect and Safety in an On-going Pilot Randomized Double-Blinded Trial

• Indinavir+AZT/3TC: Merck's study #035 (8/5/96)

• Antiretroviral-Naive Subjects Chronically Infected With HIV-1 (7/22/96) Triple therapy with nelfinavir in combination with AZT and 3TC -- Vancouver Abstract L.B.B. 6031, Martin Markowitz et al

• Ritonavir, ddC and AZT:  (7/18/96) Abbott French Study #208 of Triple Therapy, presented at Vancouver Abbott Symposium July 10, 1996

• 2nd Report (1/26/97)

• Report from the first 2 days - Friday January 24 (1/24/97)

• AIDS Clinical Trials Group (ACTG) Meeting (1/9/97) December 1996 in Washington, D.C. -- Summary of Proceedings

• NIH Panel to Define Principles of Therapy of HIV Infection (11/24/96) proceedings of Nov. 13-14 panel meeting in Washington, D.C.

3rd INTERNATIONAL CONGRESS ON DRUG THERAPY IN HIV INFECTION
Birmingham, Eng.              

• Report from November 5, 1996

• 2d Report from November 12, 1996

• Birmingham Update from NATAP: Nov 20

INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,  New Orleans

• REPORT FROM ICAAC - Day Two (9/17/96)
  Indinavir in combination with IL-2; The FDA and the future of AIDS clinical studies; Hydroxyurea in combination with ddI; ACTG 152--pediatrics; Neonates--viral load and progression, early treatment; Indinavir + AZT--Implications for induction & maintenance therapy

• REPORT FROM ICAAC - Day One 9/16/96
  Delavirdine interaction studies with protease inhibitors; 141W94--initial data for Glaxo's protease inhibitor; ritonavir+saquinavir combination study--12 week data; DMP-266, a new NNRTI--initial data; AIDS progression and survival data from 3TC clinical endpoint study

XI INTERNATIONAL CONFERENCE ON AIDS
Vancouver, July 9-12, 1996

• FINAL REPORT FROM VANCOUVER: CNS Penetration and HIV - July 12

• 4th DAY OF CONFERENCE - July 11

• 3rd DAY OF CONFERENCE - July 10

• 2nd DAY OF CONFERENCE - afternoon session July 9

• 1st DAY OF CONFERENCE - July 8

• 3rd DAY - July 7

• 2nd DAY - July 6

• 1st REPORT FROM VANCOUVER - July 4

REPORTS from the HUMAN RETROVIRUS CONFERENCE
Washington, DC.,  January 28-February 1, 1996

• 1st day of conference protease inhibitors; data on Merck Crixivan studies; early intervention; rotinavir; IL-2.

• 2nd day of conference viral load tests, disease progression and survival; clinical endpoint studies; early intervention.

• 3rd and 4th days of conference viral load, disease progression and survival; application for approval of viral load test; data on ritonavir/AZT/ddC study; Crixivan/AZT/ddI study; Agouron's Viracept/d4T study; Crixivan/AZT/3TC study.